Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy (MADIT-CHIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02164721|
Recruitment Status : Completed
First Posted : June 17, 2014
Last Update Posted : April 12, 2019
|Condition or disease||Intervention/treatment||Phase|
|Cardiomyopathy||Device: Three-lead CRT-D (Defibrillator)||Not Applicable|
With the advent of new therapies and an increasing number of long-term cancer survivors, the incidence and consequently the interest in chemotherapy-induced cardiomyopathy (CHIC) have been increasing. CHIC is a dose-dependent cardiomyopathy and presents as congestive heart failure several months to years after the administration of chemotherapy and/or chest radiation that includes the heart.
Greater than one-half of the patients exposed to just this class of drugs will show evidence of cardiac dysfunction, with 5% presenting with overt symptomatic heart failure. The overall incidence of CHIC is significantly underestimated as within the US alone, greater than 60,000 patients receive just anthracyclines every year. Despite this, there is little data on their response to conventional heart failure therapy. There is some preliminary evidence from two small, retrospective case-series suggesting that patients with CHIC and evidence of conduction tissue disease (i.e. a wide QRS duration) may significantly benefit from cardiac resynchronization therapy (CRT).
MADIT-CHIC is a multicenter, non-randomized, prospective observational study. The primary aim is to determine if CRT-D (Defibrillator) in high-risk patients with chemotherapy-induced cardiomyopathy will significantly improve left ventricular ejection fraction (LVEF) by echocardiography within 6 months of initiating CRT without adversely affecting mortality.
The study will last 6 months and will be conducted in 10-15 clinical centers in the United States.
Following implantation of the CRT-D device (Defibrillator), patients will be followed for 6 months. The first follow-up contact will be by phone at which time study personnel will review the patient's health status. The last study contact will be a 6-month clinic visit. At the 6-month visit, the patient's health status will be reviewed, the functioning of the CRT-D (Defibrillator) will be tested and an echocardiogram will be conducted. After the 6-month visit, the study-required follow-up will have been completed and patients will continue to have CRT-D (Defibrillator) clinical follow-up based on their physicians direction.
During the course of the study, Subjects will as outlined in the inclusion criteria continue on stable optimal pharmacologic therapy for the cardiac condition that is guideline-based and may include one or more of the following medications: Loop diuretics, Angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB), Aldosterone antagonists and/or Beta-blockers unless the subject is not indicated, contraindicated, or is intolerant of medication.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy|
|Study Start Date :||November 2014|
|Actual Primary Completion Date :||February 6, 2019|
|Actual Study Completion Date :||February 6, 2019|
Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
Device: Three-lead CRT-D (Defibrillator)
The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
- Change in Left Ventricular Ejection Fraction [ Time Frame: 6 months post implant ]The primary endpoint will be the change in left ventricular ejection fraction (LVEF) from baseline to six months
- Effects of CRT on all-cause mortality [ Time Frame: 6 months post implant ]Determine the effects of CRT on all-cause mortality
- Effects of CRT therapy on left ventricular volume at end systole and end diastole [ Time Frame: 6 months post implant ]Determine based on echocardiogram study if CRT therapy improves left ventricular volume at end systole and end diastole between baseline and six months
- Change in NYHA (New York Heart Association) functional class [ Time Frame: 6 months post implant ]Change in NYHA functional class between baseline and six months
- Change in left atrial size [ Time Frame: 6 months post implant ]Change in left atrial size between baseline and six months
- Effects of CRT on frequency of heart failure [ Time Frame: 6 months post implant ]Effects of CRT on the frequency of heart failure with end point of inpatient hospitalization with augmented treatment for heart failure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02164721
|United States, California|
|UCLA Cardiovascular Center|
|Los Angeles, California, United States, 90095|
|United States, District of Columbia|
|MedStar Washington Hospital Center|
|Washington, District of Columbia, United States, 20010|
|United States, Florida|
|University of South Florida|
|Tampa, Florida, United States, 33606|
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|United States, Missouri|
|Saint Louis, Missouri, United States, 63110|
|United States, New York|
|New York Presbyterian Hospita/Columbia University Medical Center|
|New York, New York, United States, 10032|
|Univeristy of Rochester Medical Center|
|Rochester, New York, United States, 14642|
|United States, Tennessee|
|Vanderbilt University Medical Center|
|Nashville, Tennessee, United States, 37232|
|United States, Texas|
|MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Valentina Kutyifa, MD, PhD||University of Rochester|